medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2019, Number 1

<< Back Next >>

Ann Hepatol 2019; 18 (1)

Rescue Therapy for Genotype-3 DAA Non-responders, Almost all Done

Llerena S, Cabezas J, Cuadrado A, Olmos JM, González M, García F, Cobo C, Crespo J

Language: English
References: 8
Page: 236-239
PDF size: 127.72 Kb.


ABSTRACT

Nowadays, the retreatment of patients with Hepatitis C virus (HCV) genotype 3 (GT3) especially cirrhotic, who have already been treated with regimens containing a NS5A inhibitor represents a challenge. Use a novel retreatment option for patients with a difficult approach. We present three case reports of retreatment with a new combination of Direct-acting antivirals (DAAs), Sofosbuvir, Elbasvir/ Grazoprevir in patients with GT3 with a previous failure with Sofosbuvir/Ledipasvir. All the cases achieved sustained virologic response (SVR) at week +12 without adverse effects. In our experience, this combo may represent an effective and safe option for these patients.


REFERENCES

  1. European Association for the Study of the Liver. Electronic address eee. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol 2017; 66: 153-94. DOI: 10.1016/ j.jhep.2016.09.001.

  2. Lawitz E, Poordad F, Gutierrez JA, Wells JT, Landaverde CE, Evans B, Howe A, et al. Short-duration treatment with elbasvir/ grazoprevir and sofosbuvir for hepatitis C: A randomized trial. Hepatology 2017; 65: 439-50.DOI: 10.1002/ hep.28877

  3. De Ledinghen V, Leforest C, Hezode C, Pol S, Renault A, Alric L, Larrey DG, et al. Retreatment with Sofosbuvir + Grazoprevir + Elbasvir + Ribavirin of Patients with Hepatitis C Virus Genotype 1 or 4 with RASs at Failure of a Sofosbuvir + Ledipasvir or + Declatasvir or + Simeprevir Regimen. American Association for the Study of Liver Diseases (AASLD); 2016.

  4. Foster GR, Agarwal K, Cramp M, Moreea S, Barclay S, Collier J, Brown AS, et al. Elbasvir/Grazoprevir plus Sofosbuvir ± Ribavirin in Treatment-naive and Treatment-experienced Patients with Hepatitis C Virus Genotype 3 Infection and Compensated Cirrhosis: The C-ISLE Study. Vol. 64. The Liver Meeting Boston: 2016; Abstract Supplement. AASLD 2016, p. 39A.

  5. Bourlière M, Gordon SC, Ramji A, Ravendhran N, Tran TT, Hyland RH, ZHang J, et al. Sofosbuvir/velpatasvir/voxilaprevir for 12 weeks as a salvage regimen in NS5A inhibitor experienced patients with genotype 1-6 infection: The phase 3 POLARIS-1 study [Abstract 194]. Vol 64. 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); 2016, p. 102A.

  6. Gane E, Poordad F, Wang S, Asatryan A, Kwo PY, Lalezari J, Wyles DL, et al. High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis. Gastroenterology 2016; 151: 651-9 e1.DOI: 10.1053/j.gastro.2016.07.020

  7. Serfaty L, Pianko S, Ben-Ari Z, Laursen AL, Hansen J, Gane EJ, Huang H, et al. High SVR rates in patients with chronic HCV GT1, 2 or 3 infection following 16 weeks of MK-3682/ grazoprevir/MK-8408 plus ribavirin after failure of 8 weeks of therapy (Part C of C-CREST-1 & 2) Vol 64. Abstract 112. American Association for the Study of Liver Disease (AASLD); 2016, p. 61A

  8. Palladino C, Sanchez-Carrillo M, Mate-Cano I, Vazquez-Moron S, Jimenez-Sousa MA, Gutierrez-Rivas M, Resino S, et al. Low frequency of NS5A relevant resistance-associated substitutions to Elbasvir among hepatitis C virus genotype 1a in Spain: a cross-sectional study. Sci Rep 2017; 7: 2892.DOI: 10.1038/s41598-017-02968-7




2020     |     www.medigraphic.com